After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. More: Novartis' prostate cancer drug Pluvicto wins key FDA nod toward B-plus sales target Source:
read moreDate: April 29-May 1, 2025 | San Diego, CA Pharma marketers crave real talk. Hear how AI, omnichannel, and peer insights are reshaping strategy in this Fierce Pharma Engage preview. Learn more & Register Today! More: Pharma Marketing in 2025:
read moreAfter failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease med Kisunla also got a rejection from EU regulators. More: Eli Lilly's Alzheimer's contender Kisunla gets thumbs down from EU regulators over safety
read moreAs U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is courting foreign investment as well, including from drugmakers. More: AstraZeneca, Sanofi, Lilly, Pfizer CEOs meet with Xi Jinping
read moreGilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since he took the reins in 2019. O’Day received a compensation package of $23.7 million last year, a 5% boost
read more
New therapy developed to repair GJB2 R75W mutation More: Genome editing offers hope for genetic hearing loss Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals